These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 33028340)
21. The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants. Hall OT; Entrup P; Farabee K; Qin H; Rizvi H; Rausch J; Felkel WC; Teater J Subst Use Misuse; 2024; 59(2):312-315. PubMed ID: 37861246 [No Abstract] [Full Text] [Related]
22. High-dose buprenorphine for treatment of high potency opioid use disorder. Danilewitz M; McLean M Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109 [TBL] [Abstract][Full Text] [Related]
23. Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users. Lubman D; Koutsogiannis Z; Kronborg I Drug Alcohol Rev; 2003 Dec; 22(4):433-6. PubMed ID: 14660133 [TBL] [Abstract][Full Text] [Related]
24. Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting. Pélissier F; Rougé Bugat ME; Nubukpo P; Franchitto N J Clin Psychopharmacol; 2016 Feb; 36(1):100-3. PubMed ID: 26658085 [No Abstract] [Full Text] [Related]
25. 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method. Azar P; Wong JSH; Mathew N; Vogel M; Perrone J; Herring AA; Krausz RM; Montaner JSG; Greenwald MK; Maharaj AR J Addict Med; 2023 Mar-Apr 01; 17(2):233-236. PubMed ID: 36149002 [TBL] [Abstract][Full Text] [Related]
26. Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial. Shulman M; Greiner MG; Tafessu HM; Opara O; Ohrtman K; Potter K; Hefner K; Jelstrom E; Rosenthal RN; Wenzel K; Fishman M; Rotrosen J; Ghitza UE; Nunes EV; Bisaga A JAMA Netw Open; 2024 May; 7(5):e249744. PubMed ID: 38717773 [TBL] [Abstract][Full Text] [Related]
27. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report. Coish R; Hardial J J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416 [TBL] [Abstract][Full Text] [Related]
28. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. Ruan X; Chen T; Gudin J; Couch JP; Chiravuri S J Opioid Manag; 2010; 6(4):300-3. PubMed ID: 20862910 [TBL] [Abstract][Full Text] [Related]
29. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects. Wachman EM; Saia K; Miller M; Valle E; Shrestha H; Carter G; Werler M; Jones H Clin Ther; 2019 Sep; 41(9):1681-1689. PubMed ID: 31358302 [TBL] [Abstract][Full Text] [Related]
30. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment. Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846 [TBL] [Abstract][Full Text] [Related]
31. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial. Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025 [TBL] [Abstract][Full Text] [Related]
32. Detoxification and treating opioid dependence. de Jong CJ JAMA; 2006 Feb; 295(8):887; author reply 887-8. PubMed ID: 16493098 [No Abstract] [Full Text] [Related]
33. Retrospective Review of a Novel Approach to Buprenorphine Induction in the Emergency Department. Dunkley CA; Carpenter JE; Murray BP; Sizemore E; Wheatley M; Morgan BW; Moran TP; Steck A J Emerg Med; 2019 Aug; 57(2):181-186. PubMed ID: 31060846 [TBL] [Abstract][Full Text] [Related]
34. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection. Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871 [No Abstract] [Full Text] [Related]
35. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder. Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432 [TBL] [Abstract][Full Text] [Related]
36. Impact of Administering Buprenorphine to Overdose Survivors Using Emergency Medical Services. Carroll G; Solomon KT; Heil J; Saloner B; Stuart EA; Patel EY; Greifer N; Salzman M; Murphy E; Baston K; Haroz R Ann Emerg Med; 2023 Feb; 81(2):165-175. PubMed ID: 36192278 [TBL] [Abstract][Full Text] [Related]
37. Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials. Shulman M; Hu MC; Sullivan MA; Akerman SC; Fratantonio J; Barbieri V; Nunes EV; Bisaga A Drug Alcohol Depend; 2022 Apr; 233():109343. PubMed ID: 35131528 [TBL] [Abstract][Full Text] [Related]
38. Opioid Withdrawal Precipitated by Long-Acting Antagonists. Kunzler NM; Wightman RS; Nelson LS J Emerg Med; 2020 Feb; 58(2):245-253. PubMed ID: 32005608 [TBL] [Abstract][Full Text] [Related]
39. Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study. Jones BLH; Geier M; Neuhaus J; Coffin PO; Snyder HR; Soran CS; Knight KR; Suen LW Harm Reduct J; 2024 Apr; 21(1):80. PubMed ID: 38594721 [TBL] [Abstract][Full Text] [Related]
40. CE: Acute Pain Management for People with Opioid Use Disorder. Broglio K; Matzo M Am J Nurs; 2018 Oct; 118(10):30-38. PubMed ID: 30211703 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]